![Cardiac Trials on X: "ARBs for HFpEF? A 2b recommendation in the latest guidelines, due in large part to hospitalization reduction in this now 20 year-old trial. CHARM-Preserved Trial, Lancet 2003 ♥️ Cardiac Trials on X: "ARBs for HFpEF? A 2b recommendation in the latest guidelines, due in large part to hospitalization reduction in this now 20 year-old trial. CHARM-Preserved Trial, Lancet 2003 ♥️](https://pbs.twimg.com/media/GIpTi16bAAEPGQS.jpg:large)
Cardiac Trials on X: "ARBs for HFpEF? A 2b recommendation in the latest guidelines, due in large part to hospitalization reduction in this now 20 year-old trial. CHARM-Preserved Trial, Lancet 2003 ♥️
![Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial - ScienceDirect Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0140673603142833-gr2.gif)
Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial - ScienceDirect
![Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial - ScienceDirect Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0140673603142857-gr1.gif)
Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial - ScienceDirect
![Figure 2 from Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial | Semantic Scholar Figure 2 from Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/ff2a649ad2496775a497804af4658a751daade79/3-Figure2-1.png)
Figure 2 from Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial | Semantic Scholar
![Relationship of background ACEI dose to benefits of candesartan in the CHARM-Added trial. - ppt download Relationship of background ACEI dose to benefits of candesartan in the CHARM-Added trial. - ppt download](https://images.slideplayer.com/29/9485351/slides/slide_2.jpg)
Relationship of background ACEI dose to benefits of candesartan in the CHARM-Added trial. - ppt download
![PDF] Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial | Semantic Scholar PDF] Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/569ebf85700d1ed65585fd33c90b0480ff26f05b/3-Figure2-1.png)
PDF] Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial | Semantic Scholar
Candesartan in Heart Failure Candesartan in Heart Failure | PDF | Heart Failure | Medical Treatments
![The CHARM Trial: CHemotherapy for Ablation and Resolution of Mucinous Pancreatic Cysts - Medical Update The CHARM Trial: CHemotherapy for Ablation and Resolution of Mucinous Pancreatic Cysts - Medical Update](https://medicalupdate.pennstatehealth.org/wp-content/uploads/2015/01/charm-image1.jpg)
The CHARM Trial: CHemotherapy for Ablation and Resolution of Mucinous Pancreatic Cysts - Medical Update
![Cumulative number of hospital admissions: CHARM-Alternative (top left),... | Download Scientific Diagram Cumulative number of hospital admissions: CHARM-Alternative (top left),... | Download Scientific Diagram](https://www.researchgate.net/publication/7027665/figure/fig1/AS:601667225526322@1520460053674/Cumulative-number-of-hospital-admissions-CHARM-Alternative-top-left-CHARM-Added-top.png)
Cumulative number of hospital admissions: CHARM-Alternative (top left),... | Download Scientific Diagram
![Results of the CHARM trial program. 52–55 Notes: *p for heterogeneity... | Download Scientific Diagram Results of the CHARM trial program. 52–55 Notes: *p for heterogeneity... | Download Scientific Diagram](https://www.researchgate.net/publication/40895788/figure/fig5/AS:339640008626189@1457987896773/Results-of-the-CHARM-trial-program-52-55-Notes-p-for-heterogeneity-037-p-for.png)
Results of the CHARM trial program. 52–55 Notes: *p for heterogeneity... | Download Scientific Diagram
![PPT - CHARM Program: 3 Component trials comparing candesartan with placebo PowerPoint Presentation - ID:778750 PPT - CHARM Program: 3 Component trials comparing candesartan with placebo PowerPoint Presentation - ID:778750](https://cdn0.slideserve.com/232610/candesartan-in-heart-failure-dt.jpg)
PPT - CHARM Program: 3 Component trials comparing candesartan with placebo PowerPoint Presentation - ID:778750
![Candesartan in Heart Failure Presented at European Society of Cardiology 2003 CHARM Trial. - ppt download Candesartan in Heart Failure Presented at European Society of Cardiology 2003 CHARM Trial. - ppt download](https://images.slideplayer.com/32/9852680/slides/slide_7.jpg)